Introduction
CC-chemokine ligand 2 (CCL2, formally known as monocyte chemoattractant protein 1), a member of the C-C chemokine family, is produced by macrophages, microglia, activated astrocytes and endothelial cells to recruit circulating monocytes to sites of inflammation. 1 Owing to its importance in inflammatory responses, increased levels of CCL2 have been implicated in a variety of disease pathologies including arthersosclerosis, cancer metastisis, multiple sclerosis, Alzheimer's disease and human immunodeficiency virus-associateddementia (HIV-D). [2] [3] [4] [5] [6] [7] In other settings, CCL2 appears to be beneficial as it protects against initial HIV infection, is neuroprotective against HIV Tat and N-methyl-D-aspartate-induced apoptosis during early HIV infection, and promotes healing following myocardial infarct. [8] [9] [10] Genetic analysis of the distal CCL2 promoter revealed a polymorphism at À2578 (alternatively designated À2518
11
) with functional consequences in the context of a luciferase reporter assay. Specifically, CCL2 distal promoters that harbor the À2578 G allele exhibit higher levels of activity than those harboring the A allele in interleukin (IL)-1b-stimulated cells. 11 Other studies demonstrated that the guanine polymorphism increased the levels of CCL2 produced in cultured peripheral blood mononuclear cells, monocytes and hepatic stellate cells providing evidence that the polymorphism regulates CCL2 expression in the context of the endogenous promoter. [11] [12] [13] [14] [15] [16] Almost 6 years ago, a provocative study associated the À2578 G allele with protection against initial HIV infection; however, once individuals were infected, they exhibited a more rapid progression to acquired immune deficiency syndrome and a 4.5-fold increased chance of developing HIV-D compared to individuals carrying the ancestral À2578 A allele. 9 Preliminary molecular analysis in this study suggested that the region encompassing the À2578 polymorphism shared homology with an interferon-stimulated response element (ISRE) and that the transactivator interferon regulatory factor (IRF)-1 bound the À2578 A allele with higher affinity than the À2578 G allele.
Presently, numerous reports have associated the À2578 G polymorphism with a wide variety of pathological sequelae such as progression of Mycobacterium turberculosis infection, earlier age of onset of idiopathic immunemediated posterior segment uveitis, asthma severity, premature kidney graft failure and hepatitis C virusrelated liver disease severity among others. [12] [13] [14] 17, 18 A number of studies have also correlated the À2578 G polymorphism with increased expression of CCL2 in vivo. For example, plasma levels of CCL2 in unaffected-individuals and patients with tuberculosis, Behcet's and Alzheimer's diseases were significantly higher in individuals that harbor the À2578 G allele compared to those that harbor the À2578 A allele. 3, 9, 13, 16, 19 Further, levels of CCL2 in the cerebrospinal fluid of HIV infected individuals were significantly higher in individuals that harbored the G at À2578 compared to those which harbored the A, indicating that this polymorphism influences in vivo central nervous system (CNS) levels of CCL2. 9 Finally, patients with systemic lupus erythematosus that carried the À2578 G allele demonstrated an increase in interstitial macrophages in the kidney, which is indicative of increased trafficking of monocytes into tissue, thereby providing biological significance of the À2578 G allele to increased levels of CCL2. 9 Because the majority of studies have demonstrated that the À2578 G allele confers increased expression of CCL2 in cells that are stimulated with proinflammatory cytokines as compared to the À2578 A allele, we were puzzled by a potential regulatory mechanism involving decreased binding of a classical transactivator protein (IRF-1) and intrigued by the report of a specific complex able to bind the À2578 G allele in electrophoretic mobility shift assay (EMSA) but not the A allele. 12 Here we propose a molecular model by which the À2578 G polymorphism regulates CCL2 expression in astrocytes and identify two proteins that bind as a complex specifically to the À2578 G CCL2 allele. Neither protein is a member of the IRF family (in fact, no definitive binding of IRF-1 or -2 to either À2578 allele could be demonstrated in our studies); rather, one protein was identified as Prep1 (also known as Pknox1), a member of the three amino-acid loop extension (TALE) family of proteins in the subfamily MEINOX (Meis/Pknox1), and the second protein was identified as Pbx2, a second TALE family member known to complex with Prep1. Both proteins are required to obtain binding of the complex to the À2578 G allele. With broader implications perhaps relevant to the wide variety of diseases impacted by the À2578 polymorphism, the identification of this site as a MEINOX consensus sequence suggests that the G allele has the potential to bind any of the MEINOX family members thereby conferring cell/tissuespecific effects on expression of CCL2.
Results
Promoters that harbor the À2578 G polymorphism exhibit lower basal transcription in reporter assays Transcriptional activity of the distal promoter region of CCL2 (929 bp) has previously been studied using luciferase assays in the A172 astrocytoma cell line, which demonstrated elevated transcriptional levels for promoters that contained the À2578 G polymorphism upon IL-1b stimulation. 11 We used U87-MG cells in the present studies to examine the molecular basis of the À2578 G phenotype in another relevant astrocytic cell line widely used to study CCL2 expression [20] [21] [22] and as astrocytes are key producers of CCL2 in the brain, which promotes an influx of monocytes that correlates with HIV/simian immunodeficiency virus (SIV) encephalitis and dementia. 2 We utilized the same 929-bp distal human CCL2 promoter region as the previous study inserted into a pGL4.11 firefly luciferase vector in conjunction with a pGL4.74 renilla luciferase vector in cotransfection experiments to control transfection efficiency. Extracts prepared from transfected U87-MG cells that were either stimulated with IL-1b or left unstimulated for 3 h were subjected to Dual-Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA) to quantitate both firefly and renilla luciferase activity. A consistent reduction in the basal level of transcription was observed in cells transfected with vectors that contain the À2578 G allele as compared to the À2578 A allele (Figure 1 , P ¼ 0.0012). However, transcriptional levels were equivalent after stimulation with IL-1b ( Figure 1 , P ¼ 0.88), reflecting a greater fold induction for the À2578 G allele (Figure 1 , P ¼ 0.016). These data suggested two possibilities: (1) a transcription factor(s) binds preferentially to the À2578 A allele in unstimulated cells, providing a higher level of constitutive transcriptional activation and/or (2) a transcription factor(s) with repressor activity binds preferentially to the À2578 G promoter in unstimulated cells.
The À2578 G region of the human CCL2 promoter exhibits enhanced binding of a specific nuclear complex that does not contain IRF-1 or -2 Previous studies suggested that the À2578 region is an ISRE and that the À2578 G polymorphism disrupts the binding of the transcription activator IRF-1. 9 However, aligning the consensus-binding elements for IRF-1 and -2 with the canonical ISRE, the CCL2 ISRE and the probes used in this study (in reverse-complement orientation, Figure 2a ), revealed that an A or a G at position À2578 disrupts the ISRE consensus site where ISRE, IRF-1 and IRF-2-binding sites are 100% conserved. Although this alignment suggests that the À2578 region is a poor ISRE, we nonetheless included IRF-1 and -2 (a known repressor of ISREs) in our analyses in an effort to reconcile previously reported studies. To examine the presence of IRF-1 and -2 in U87-MG cells, we performed western blot analysis on nuclear lysates, which demonstrated that IRF-2 is constitutively expressed (Figure 2b ) and IRF-1, whereas expressed at low levels in unstimulated cells, is induced to a great extent by IL-1b (Figure 2c ). To determine whether IRF-1 and -2 bind the À2578 region, labeled double-stranded DNA oligonucleotides containing either the À2578 A or G polymorphism were subjected to EMSA analysis in parallel with labeled ISRE consensus double-stranded DNA oligonucleotides that provided a control for specific IRF-1 and -2 binding. As expected, IRF-2 bound the ISRE consensus oligonucleotide producing a distinct band (Figure 2d EMSA analysis of nuclear extracts from U87-MG cells clearly revealed a protein complex that binds specifically to the À2578 G oligonucleotide (Figures 2d and e , lanes 7 and 8) consistent with a previous report, 12 although weak binding to the À2578 A oligonucleotide was observed (Figures 2d and e, lanes 5 and 6) . Notably, this band is not present in the ISRE consensus lanes and is not affected by the addition of either IRF-2 or -1 antibody. Competition experiments using unstimulated U87-MG nuclear extracts incubated with the À2578 A-labeled oligonucleotide again demonstrated weak binding of the complex compared to the À2578 G oligonucleotide (Figure 2h , lanes 2 and 1, respectively) which was competed away by 100 Â unlabeled À2578 A and G oligonucleotides (Figure 2h, lanes 3 and 4) but not unlabeled ISRE or scrambled G oligonucleotides (Figure 2h, lanes 5 and 6) . Competition experiments using labeled À2578 G oligonucleotides demonstrated notable but incomplete competition with 100 Â unlabeled À2578 A oligonucleotides (Figure 2i , lane 3), complete competition with 100 Â unlabeled À2578 G oligonucleotides (Figure 2i , lane 4) and no competition with 100 Â unlabeled ISRE and scrambled À2578 G oligonucleotides (Figure 2i , lanes 5 and 6, respectively). Collectively, these observations suggest that a protein complex exists (not containing IRF-1 or -2) that has a high affinity for the À2578 G allele and binds only weakly to the À2578 A allele.
The À2578 G polymorphism creates a consensus-binding site (TGACAG) for the MEINOX proteins in the TALE family To identify factors that potentially bind the À2578 region, a search was conducted using MatInspector (Geomatrix), which identified the G allele but not the A allele as the Meis1 consensus-binding site (Figure 3a) . The Meis1 consensus site, TGACAG, is shared by the other members of the MEINOX subclass of TALE proteins and exhibits 100% sequence alignment to the À2578 G region. To investigate whether the MEINOX consensus site is required for the G-specific band, we first compared the binding of U87-MG nuclear lysates to an oligonucleotide reported by Chang et al. 23 that was used to define the Meis consensus site (herein referred to as the Chang oligonucleotide) in parallel with the À2578 A and G oligonucleotides by EMSA. The intensity of the band for the À2578 A oligonucleotide was very weak, but the band increased in intensity in the presence of À2578 G oligonucleotides with the highest intensity observed in the presence of Chang oligonucleotides (Figure 3b 
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Relative Luciferase Activity Figure 1 The À2578 G polymorphism influences basal activity of the CCL2 distal promoter. Distal promoters (929 bp) harboring either the À2578 G or A polymorphism were cloned directly upstream of the firefly luciferase gene in the pGL4.11 vector. Constructs were transfected into U87-MG cells (human astrocytic cell line) along with pGL4.74, a renilla luciferase construct that serves to control for transfection efficiency. pGL4 vectors without inserts resulted in nominal background luciferase activity (not shown). Transfected cells were either untreated or treated with human recombinant interleukin (IL)-1b (10 ng ml
À1
) for 3 h. Results are presented relative to the À2578 A construct. (a) Basal activity for the À2578 G construct is significantly lower than the À2578 A construct (P ¼ 0.0012). (b) IL-1b-stimulated activity is equal for constructs containing either the À2578 G or A allele (P ¼ 0.88). (c) The fold induction is greater for the À2578 G construct (P ¼ 0.016) as compared to the A construct. The results represent the mean of four individual experiments in which samples were processed in triplicate, controlled for transfection efficiency and normalized to the À2578 A construct. . Bold nucleotides represent nucleotides in the CCL2 ISRE that do not match the consensus-binding sequences. Bold/italicized nucleotides highlight the location of the À2578 polymorphism, where neither polymorphism matches the consensus sequence. Western blot analysis to identify IRF-2 (b) and IRF-1 (c) in nuclear extracts from unstimulated U87-MG cells and U87-MG cells stimulated with 10 ng ml À1 interleukin (IL)-1b (a known activator of IRF-1) for 2.5 h. EMSAs were performed using the unstimulated (d) and IL-1b-stimulated (e) U87-MG nuclear lysates with labeled ISRE consensus oligonucleotide, À2578 A and G oligonucleotides. Antibodies were added to binding reactions as indicated above the gel lanes; ss, antibody complex resulting from supershift analysis using a-IRF-2 and a-IRF-1; IRF-2, indicates band that contains IRF-2 as part of the complex; IRF-1, indicates band that contains IRF-1 as part of the complex; GSC, protein complex that is specific to the À2578 G oligonucleotide. Competition EMSAs were performed using 200 Â unlabeled ISRE oligonucleotide (lane 2), À2578 A oligonucleotide (lane 3), À2578 G oligonucleotide (lane 4) and scrambled G oligonucleotide (lane 5, to account for nonspecific effects) with either unstimulated (f) or IL-1b-stimulated (g) U87-MG nuclear extracts. To determine the specificity of the intense band present in the À2578 G lanes of the ISRE EMSA (d, e, lanes 7 and 8), competition EMSAs were performed using 100 Â unlabeled oligonucleotide of À2578 A oligonucleotide, À2578 G oligonucleotide, ISRE consensus oligonucleotide and scrambled G oligonucleotide against labeled À2578 A oligonucleotide (h) and labeled -2578 G oligonucleotide (i) using unstimulated U87-MG nuclear lysates. The G-specific band is the only region shown for each EMSA because Prep1/Pbx2 complexes bind CCL2 À2578 G region EK Wright et al their common TGACAG consensus sites (Figure 3a) , the labeled Chang oligonucleotide migrated with the labeled G oligonucleotide, suggesting that the core sequence shared by both oligos is necessary for binding of this complex. To examine whether the À2578 G oligonucleotide and the Chang oligonucleotide bound the same protein complexes, competition experiments were performed with labeled À2578 G or Chang oligonucleotides and 100 Â of each unlabeled oligonucleotide. Competition of labeled À2578 G complexes with 100 Â unlabeled À2578 A oligonucleotide reduced the G-specific band but not completely as shown above (Figure 3c , lane 3), whereas complete competition was observed with 100 Â unlabeled À2578 G and Chang oligonucleotides and no competition was observed with 100 Â unlabeled scrambled À2578 G oligonucleotide (Figure 3c , lanes 4, 5 and 6, respectively). Competition of labeled Chang complexes with 100 Â unlabeled À2578 A oligonucleotide only slightly decreased the intensity; competition with 100 Â unlabeled À2578 G oligonucleotide competed better than the À2578 A oligonucleotide but did not completely compete for the Chang complexes (Figure 3d , lanes 3 and 4), which occurred only with 100 Â unlabeled Chang oligonucleotide (Figure 3d , lanes 5). These results suggest that (1) the protein complex that binds the À2578 G oligonucleotide can bind the Chang oligonucleotide; G M u t a n t 1 C M u t a n t 8 C M u t a n t 5 C M u t a n t 7 T M u t a n t 3 C M u t a n t 6 A M u t a n t 2 A -2 5 7 8
A -2 5 7 8 G M u t a n t 1 C M u t a n t 8 C M u t a n t 5 G M u t a n t 7 T M u t a n t 3 G M u t a n t 6 A M u t a n t 2 A -2 5 7 8 
oligonucleotide, possibly due to residues outside the core TGACAG. The Chang oligonucleotide has a Pbx consensus site (TGAT) adjacent to the MEINOX-binding site (TGACAG), which is absent from the À2578 G oligonucleotide. As many of the MEINOX proteins have to complex to Pbx proteins to enter the nucleus and regulate transcription, it seemed likely that the MEINOX protein that is bound to the À2578 G oligonucleotide and the Chang oligonucleotide may be complexed with its Pbx-binding partner.
To further investigate whether the À2578 G site is a MEINOX consensus site, we mutated the MEINOX consensus site in the À2578 G oligonucleotide one nucleotide at a time and tested mutated oligonucleotides in EMSA experiments. For simplicity, pyrimidines were mutated to pyrimidines and purines were mutated to purines (Figure 3f ). Previous analyses defining in vitro monomeric Meis1 high affinity consensus site from binding site selection experiments. 23 ( Figure 3e ) suggested that positions 3 and 5 could tolerate an A to G mutation at those sites but not a C; therefore, those sites were also mutated to C as well. EMSA analysis of the mutant panel consisting of all transition changes (Figure 3g ) demonstrates that positions 2 (lane 3) and 4 (lane 5, À2578 polymorphic site) could not tolerate mutational changes and binding to the G-specific band pattern was lost, results that are strikingly consistent with previous studies that demonstrate position 2 does not tolerate nucleotide substitution for binding of Meis1 and Prep1. 23, 24 Mutant oligonucleotides 1, 3, 5, 6 bound the protein complex but with reduced band intensity (lanes 2, 4, 6 and 7, respectively), whereas mutant oligonucleotides 7 and 8 bound the complex with equal intensity as the À2578 G nucleotide (lanes 8 and 9, respectively); this observation is again consistent with a previous study defining the Meis1 high affinity consensus site. 23 Moreover, the band observed with the À2578 G oligonucleotide is lost when positions 3 and 5 are mutated to C (Figure 3h, lanes 4 and 6, respectively) , [23] [24] [25] Western blot analysis was used to examine the expression of MEINOX proteins in unstimulated and IL-1b-stimulated U87-MG cells, which demonstrated that all five proteins were expressed (Figures 4a and b; data not shown). Western blot analysis was also used to Figure 4 Prep1 and Pbx2 complexes bind the À2578 G allele. Western blot analysis of nuclear extracts from unstimulated U87-MG cells and U87-MG cells stimulated with 10 ng ml À1 interleukin (IL)-1b for 2.5 h for (a) Prep1, (b) Pbx2 (a known binding partner of Prep1) and (c) Meis-2; no protein expression could be visualized for Pbx1 (the other known binding partner for prep1, data not shown). (d) Electrophoretic mobility shift assay (EMSA) performed using the unstimulated U87-MG nuclear lysates with labeled À2578 A oligonucleotide (lane 1) or the À2578 G oligonucleotide (lanes 2-6). Antibodies were added to binding reactions as indicated above the gel lanes; ss, antibody complex resulting from supershift analysis using a-Pbx2. U87-MG cells were transfected with small-interfering RNAs (siRNA) for Prep1, Pbx2 and Meis2 as well as with the risk-free siGlo and nontargeting controls. (e) Western blot analysis of whole cell lysates from transfected cells using antibody against Prep1, Pbx2, Meis2 and actin (loading control). (f) Nuclear lysates from U87-MG cells extracted 36 h after siRNA tranfection were used in EMSA experiments with labeled À2578 G oligonucleotide. Labeled interferon-stimulated response element (ISRE) consensus oligonucleotide was added to each reaction to use the IRF-2 band for quantitation purposes. Figure 4f is representative of three independent experiments. (g) Prep1 (upper gel) and Pbx2 (bottom gel) were coimmunoprecipitated from unstimulated U87-MG nuclear lysates and detected by western blot. The G-specific band is the only region shown in some EMSAs because Figures 2d and e (lanes 7 and 8) clearly show that lanes containing the G-specific band are void of nonspecific bands. Data are representative of at least two independent experiments. Prep1/Pbx2 complexes bind CCL2 À2578 G region EK Wright et al examine the expression of Pbx-binding partners in unstimulated and IL-1b-stimulated U87-MG cells, which demonstrated constitutive expression of Pbx2 (Figure 4c ), but failed to detect Pbx1 (which could not be detected by reverse transcriptase (RT)-PCR using mRNA from the U87-MG cells; data not shown). Meis1, Meis2, Meis3, Prep1, Prep2 and Pbx2 expression in U87-MG cells was further confirmed by cloning and sequencing of RT-PCR amplification products from U87-MG mRNA (data not shown).
To determine whether any of these proteins are present in the complex that binds the À2578 G oligonucleotide, antibodies against each of the expressed TALE proteins in addition to an isotype control antibody was added to EMSA reactions (Figure 4d ). Addition of Prep1 and Meis2 antibodies ablated the G-specific band (lanes 3 and 5), whereas addition of Pbx2 antibody supershifted the complex and reduced the intensity of the remaining G-specific band (Figure 4d, lane 5) . Isotype control antibody as well as antibody against Meis1, Meis3 and Prep2 did not affect the À2578 G oligonucleotide complex ( Figure 4d , lane 6; data not shown). EMSAs using IL-1b-stimulated U87-MG nuclear extracts and TALE antibodies were identical to the EMSAs using the unstimulated U87-MG cells, further supporting the binding of TALE proteins to the À2578 G oligonucleotide (data not shown).
Since Prep1 and Meis2 have not been previously demonstrated to exist in a complex, we considered the possibility that one or both antibodies are cross-reactive, a common problem with MEINOX antibodies due to the high homology between all MEINOX family members. Western blots of in vitro-translated Prep1 and Meis2 confirmed that both antibodies recognized both proteins (data not shown). Therefore, to determine which one of these MEINOX proteins potentially bound the À2578 G oligonucleotide with Pbx2, we knocked down the expression of each protein specifically with smallinterfering RNAs (siRNAs). Western blot analysis of whole cell extracts of U87-MG cells transfected with individual siRNAs, left unstimulated or stimulated with IL-1b, demonstrate significant reduction of Prep1, Pbx2 and Meis2 expression by 48-72 h after transfection (Figure 4e, lanes 4, 5 and 6 , respectively, data not shown). Nuclear lysates prepared from unstimulated U87-MG cells transfected with the individual siRNAs for 36 h were used in an EMSA assay. To quantify the effect on binding, labeled ISRE oligonucleotide was added to the À2578 G-labeled oligonucleotide prior to addition to the EMSA reactions and the resulting IRF-2/ISRE band (see Figure 2d demonstrating ISRE specificity) was used to normalize the G-specific band in each reaction. The ratio of the G-specific band to the IRF-2 band was 3.35 for no siRNA, 3.78 for siGlo risk-free control and 3.66 for the nontargeting siRNA control (Figure 4f, lanes 2, 3 and 4) . The siRNA against Prep1 clearly abolishes binding of the protein complex to the À2578 G probe (Figure 4f , lane 5, G/IRF-2 ratio ¼ 0.77), whereas siRNA against Pbx2 reduces the intensity of the band but does not completely abolish the binding of the complex (Figure 4f , lane 6, G/ IRF-2 ratio ¼ 2.21). However, siRNA against Meis2 did not reduce the G-specific band (Figure 4f , lane 7, G/IRF-2 ratio ¼ 3.50) indicating that Meis2 is not present in the protein complex that binds the À2578 G oligonucleotide. The results were identical using siRNA-transfected IL1b-stimulated U87-MG cells, demonstrating the same binding specificity in stimulated cells (data not shown).
The Prep1 and Pbx2 siRNA experiments demonstrated that both of these proteins bound the À2578 G oligonucleotide, but did not exclude the possibility that these proteins bind individually to the À2578 G oligonucleotide. However, the G-specific band was reduced in intensity with siRNA against either Prep1 or Pbx2, suggesting that neither protein could bind the À2578 G oligonucleotide when not in complex with its partner. To directly examine the potential interaction between Prep1 and Pbx2, nuclear extracts from unstimulated U87-MG cells were subjected to reciprocal immunoprecipitation and western analysis with antibody against Prep1 or Pbx2, which demonstrated that these proteins do exist in a complex (Figure 4g ). In additional experiments neither Prep1 nor Pbx2 could bind the À2578 G oligonucleotide in an EMSA assay when transcribed/translated separately in vitro; however, when Prep1 and Pbx2 were transcribed/translated together, a complex bound the À2578 G oligonucleotide providing additional evidence that both Prep1 and Pbx2 have to be present for binding (data not shown). Collectively, these observations support the conclusion that Prep1/Pbx2 complexes exist in astrocytes and bind specifically to the À2578 G allele.
Discussion
The À2578 G polymorphism in the CCL2 distal promoter is an example of a functional promoter polymorphism that associates with disease pathogenesis, correlates with protein levels in vivo and affects reporter gene expression 3, 9, [11] [12] [13] [14] [15] [16] 19 ( Figure 1 ). In the present study, we have investigated the À2578 polymorphism in an astrocytic cell line to model the influence of this site in the brain. Astrocytes are considered to be the major producers of CCL2 in the CNS, and the À2578 G polymorphism has been associated with the development of HIV-D. 2, 9 Surprisingly, our data demonstrate that the G allele confers a repressive phenotype on promoters (compared to the A allele) in unstimulated astrocytes, which is overcome by stimulation with IL-1b such that expression from both alleles is equivalent. The subsequent effect on fold induction is consistent with previous studies, 11 causing the construct with the G allele to have a greater fold induction as compared to the A allele. Our studies also identified the À2578 G polymorphic region as a consensus site for the MEINOX family of transcription factors and demonstrated that the complex binding to the À2578 G region exhibits the same sequence specificity as the MEINOX consensus sequence. Further, we identified Prep1 as the only MEINOX family member that binds specifically to promoters that harbor the À2578 G allele in U87-MG cells and demonstrate that Prep1 is in a complex with its binding partner, Pbx2.
We could not confirm that the À2578 region is an ISRE, or that IRF-1 or -2 bind this region. IRF-1 and -2 bind the consensus ISRE oligonucleotides; however, these bands and shifts were not detected with the À2578 A and G oligonucleotide lanes. Furthermore, neither the À2578 A nor G oligonucleotides competed notably with the consensus ISRE oligonucleotide. Although these results are negative, they challenge the findings of previous work, 9 and hence must be reported. To date, no study has revealed how this polymorphism regulates transcription of CCL2 or described an alternative transcription regulator that binds this site, although numerous studies continue to investigate the effect of this polymorphism on disease outcome. In the absence of a mechanistic model, reports that explore whether the À2578 G polymorphism affects disease are stymied by the lack of intervention strategies potentially able to alleviate disease symptoms or outcome. It follows then that when the mechanism by which the À2578 G polymorphism regulates disease is understood, the possibility exists for the design of effective therapeutics to treat affected À2578 G individuals.
In this study, we demonstrate that a complex binds specifically to the À2578 G allele yielding a single band in U87-MG cells and identified two complex proteins, Prep1 and Pbx2. Prep1 can modulate the activity of Pbx1a, Pbx1b and Pbx2 depending on their expression profile, 26 and it has been previously reported that Pbx1 will also bind Prep1 in DNA-binding assays, producing a second distinct band. [26] [27] [28] [29] Previous studies have demonstrated that Prep1 is expressed ubiquitously, including all regions examined in the human brain. 30 The present studies demonstrate that astrocytic cells (U87-MG) express only Pbx2, although both Pbx1 and Pbx2 are expressed in hematopoietic (K562), epithelial (A431) and glial (Hs683) cells. 23 Cell-type-specific regulation of Prep1/Pbx-1 or-2 complexes has been well investigated and raises the possibility that the effect of the À2578 G polymorphism may differ depending on which Pbxbinding partners are expressed in the cell. Interestingly, Prep1/Pbx2 complexes have been reported to repress promoters 31, 32 as well as activate promoters 29, 33 containing the TGACAG motif in a cell-type-dependent manner, 32 whereas Prep1/Pbx1 complexes have only been reported to activate promoters. 28, 34 This study has shown that Prep1/Pbx2 nuclear complexes can bind the À2578 G oligonucleotides under unstimulated and IL-1b-stimulated conditions where promoter activity from the G allele is repressed and equivalent, respectively, as compared to the A allele. These data suggest that the À2578 site does not influence IL-1b-stimulated CCL2 expression in astrocytes. One reasonable interpretation is that during IL-1b stimulation other potent or dominant transcriptional activators of CCL2 gene expression such as nuclear factor (NF)-kB, simply overcome the repressive effect of the Prep1/Pbx2 complex. It is also conceivable that the binding of transactivators like NF-kB results in the displacement of Prep1/Pbx2 complexes in the context of an endogenous CCL2 promoter as opposed to oligonucleotides in EMSAs. Regardless, the binding of cell-type-specific activator or repressor Prep/Pbx complexes to the À2578 site, which is not known to be a major regulatory region of the CCL2 promoter, coupled with cell-typespecific activation or quiescence of the known CCL2 regulators [35] [36] [37] [38] [39] [40] [41] could account for the conflicting reports regarding the À2578 CCL2 polymorphic alleles and CCL2 levels in different disease models. For example, although several studies have associated the G allele with increased expression of CCL2 in plasma, 3, 9, 13, 16, 19 other studies have reached the opposite conclusion 42, 43 and some studies have failed to find a significant difference in CCL2 levels in individuals harboring either allele. 42 One study examining a link between this polymorphism and renal survival of Japanese patients with immunoglobulin A nephropathy associated the À2578 A allele with increased incidence of end-stage renal disease and revealed a trend in patients with immunoglobulin A nephropathy to have higher serum CCL2 levels when homozygous for the À2578 A, with a slightly lower level of serum CCL2 for heterozygotes and the lowest levels in patients homozygous for the À2578 G. 42 A similar finding was described in a study investigating the effect of the À2578 polymorphism on insulin resistance in which the À2578 G allele was associated with decreased plasma CCL2 levels and a decreased prevalence of insulin resistance. 43 These observations may well reflect the expression of specific Prep/Pbx proteins in different cells/tissues and the activation state of the CCL2 producing cells associated with each disease.
The repressive CCL2 phenotype observed in unstimulated astrocytes described above may well increase our understanding of the association between the À2578 allele and HIV-D. As discussed, astrocytes are the major producers of CCL2 in the brain and increased levels of CCL2 in the CSF lead to the recruitment of monocytes to the brain, which have been a strong correlate of HIV CNS disease. [44] [45] [46] [47] [48] Under homeostatic conditions, astrocytes from individuals expressing the G allele would be expected to produce lower levels of CCL2 compared to their A allele counterparts based on the studies presented herein. During inflammatory conditions in the brain, a greater fold induction of CCL2 expression would result in astrocytes harboring the À2578 G allele, perhaps reflected in the CSF of HIV positive À2578 G individuals as reported, 49 and create a steeper increase of CCL2 from basal levels compared to their A allele counterparts, favoring a greater influx of monocytes. We have previously demonstrated that increased levels of CSF CCL2 protein alone, in pig-tailed macaques infected with SIV, predict the development of moderate/severe CNS disease demonstrating that it is the level of CCL2 in the CNS that drives monocyte recruitment in this animal model of HIV-D. 50 Because CCL2 itself is a proinflammatory chemokine, it follows that the hyper-responsiveness of the promoters that contain the À2578 G become amplified in the self-perpetuating inflammatory cycle, resulting in further increases in CCL2 as well as other proinflammatory mediators.
Materials and methods

Materials
Antibodies to IRF-1 (sc-497 X), IRF-2 (sc-498 X), Prep1 (sc-6245 X), Pbx1 (sc-889 X), Pbx2 (sc-890 X) and TFIIB (sc-274 X) were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). 
DNA extraction
To clone CCL2 distal promoter regions, DNA was extracted from pelleted U937 and 293T cells (rationale below), using the Dneasy tissue kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions.
PCR and plasmid production
The 929 bp CCL2 promoter region was amplified by PCR from genomic DNA in 25-ml reactions with FailSafe PCR system (Epicentre Biotechnologies, Madison, WI, USA), using the forward primer 11 Prep-1 and Pbx2 were amplified from cDNA, created from U87-MG RNA, in 25-ml reactions with Platinum Taq-High Fidelity (Invitrogen) using the forward primer (Prep1) 5 0 -GGGGACAAGTTTGTA CAAAAAAGCAGGCTGATGA TGGCTACACAGACATT-3 0 and reverse primer (Prep1) 5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGCTACTG CAGGGAGTCACTGT-3 0 , and the forward primer (Pbx2) 5 0 -GGGGACAAGTTTGTACAAAAAAGCAGGCTGATG GACGAACGGCTACTGGG-3 0 and the reverse primer (Pbx2) 5 0 -GGGGACCACTTTGTACAAGAAAGCTGGGT CAGTTGGAGGTATCAGAGT-3 0 with a change in the extension time (72 1C for 2-min and 30-s) of the thermal profile above. Bold nucleotides represent the targetspecific primer sequence, whereas plain text represents additional nucleotides needed to clone using the BP reaction in the Gateway system. For the distal CCL2 region, two separate PCR reactions were completed, one with DNA from U937 cells (heterozygous at the À2578 site, but contained a single nucleotide polymorphisms at À2408 G to C on the À2578 A allele) to clone the À2578 G allele and one PCR reaction with DNA from 293T cells (homozygous À2578 A) to clone the À2578 A allele. All PCR reactions were resolved on a 1.2% agarose gel, and bands were gel purified (Invitrogen) and subjected to the gateway BP clonase reaction, which transferred the distal promoter regions, Prep1-and Pbx2-coding regions into the pDONR221 vector. The pGL4.11 vector was converted to a Gateway vector using the cassette B and following the protocol from the gateway vector conversion kit. The distal promoter regions were transferred from the pDONR 221 vectors to the converted pGL4.11 vectors through the LR clonase reaction. Distal promoter pGL4.11 vectors were sequenced to confirm that the only difference between the two vectors was the À2578 A and G site. Prep1 and Pbx2 inserts were transferred from the pDONR 221 into the pcDNA3.1/V5 and pEXP1-Dest vectors through the LR clonase reaction.
Cell culture and reagents U87-MG cells (HTB-14, American Type Culture Collection, Manassas, VA, USA) were maintained in minimum essential medium (MEM) with glutamine supplemented with 10% fetal bovine serum (FBS), 0.1 mM MEM nonessential amino acids and 1 mM sodium pyruvate. U87-MG cells are homozygous for the A allele at the À2578 position.
Luciferase assays Day 1: one T-75 flask 490% confluent of U87-MG cells was split into six-well plates containing antibiotic-free media. Day 2: the media was changed to MEM (serum free, antibiotic free) and 1440 ng of pGL4.11 (no insert, À2578 A or À2578 G) and 480 ng of pGL4.74 (Promega Corporation), to control for transfection efficiency, were transfected with Lipofectamine 2000. After 3 h of incubation at 37 1C, the media was decanted and replaced with 2% serum, antibiotic-free media. Day 3: 24 h after transfection, cells were left unstimulated or stimulated with 10 ng ml À1 IL-1b for 3 h. After stimulation, cells were washed twice with phosphate-buffered saline (PBS) and lysed with passive lysis buffer (dual luciferase assay system; Promega Corporation). Plates were scraped and the lysates were placed into 1.5 ml microcentrifuge tubes and sonicated for 20 s at 95% amplitude in a cup horn. Lysate (20 ml) was subjected to the dual luciferase assay using the Fluoroskan Ascent FL.
Firefly luciferase and renilla luciferase activities were measured for each sample. The firefly luciferase activity was normalized for transfection efficiency to the renilla luciferase values and the mean relative luciferase activity was calculated from triplicate samples in each experiment. The mean relative luciferase activity for À2578 G was normalized to the mean relative luciferase activity for À2578 A in each basal and IL-1b-stimulated experiment. Fold stimulation was calculated by dividing the mean relative luciferase activity for the A or G constructs in IL-1b-stimulated samples by the mean relative luciferase activity for the A or G constructs in basal samples, respectively. Fold stimulation for the À2578 A and À2578 G constructs were normalized to the fold stimulation for the À2578 A construct in each experiment. The normalized values of the À2578 G constructs were compared to the normalized values of the À2578 A constructs. A one-sample t-test was performed for each condition, which tested if the mean of the normalized À2578 G constructs is significantly different from À2578 A (1). All P-values presented are two-tailed.
siRNA transfection siRNAs (50 nM; none, Risc-free siGlo, nontargeting siRNA pool, PKNOX1 (Prep1), PBX2 pool and MEIS2 pool) were transfected into T-75 flasks with U87-MG cells (60% confluent) using Lipofectamine 2000. After 4 h incubation at 37 1C, media was changed to fresh MEM 10% FBS with no antibiotics. Nuclear lysates were taken from transfected U87-MG cells at 36 h after transfection, using a nuclear extraction kit and protocol (Marligen Biosciences Inc., Ijamsville, MD, USA). Whole cell lysates were extracted using RIPA (1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM NaF, 1 Â protease inhibitor cocktail (Calbiochem, Darmstadt, Germany) in 1 Â PBS) buffer with sonication.
Western blot analysis U87-MG nuclear lysates (30 mg) prepared from U87-MG cells that were stimulated or not with IL-1b for 2.5 h, or whole cell extracts from siRNA-treated U87-MG cells (50 mg) were resolved on a 10% Tris-Cl Criterion gel (BioRad Laboratories, Life Science Research, Hercules, CA, USA) and transferred to a nitrocellulose membrane with the criterion wet transfer apparatus. Membranes were washed 5 min in Tris-buffered saline Tween-20 (TBST), blocked for 20 min with 5% milk and rocked at 4 1C overnight with a- Prep1 (1:2000) , a-Pbx2 (1:2000) , a-Meis2 
EMSA analysis
Nuclear extracts were prepared from U87-MG cells (treated or not with IL-1b for 2.5 h) using a nuclear extraction kit and protocol (Marligen Biosciences Inc.). DNA-binding reactions were performed on ice for 30 min in a 15 ml reaction volume containing 2 mg of poly(d(IC)), 75 mM NaCl, 1 mM EDTA, 10 mM Tris-HCL (pH 7.5), 6% glycerol and 2 mg of bovine serum albumin and subjected to EMSA using 5% Tris-borate-EDTA (TBE) polyacrylamide gels (Bio-Rad) in 0.25 Â TBE buffer. DNA probes (50 000 c.p.m. per binding reaction) were labeled, forward and reverse strand independently, using T4 polynucleotide kinase and g-32 P-ATP. Labeling reactions for the forward and reverse oligonucleotides were then added together, immediately boiled for 5 min, left for 1 h to equilibrate to room temperature and then passed through the G25 spin columns to separate oligonucleotides from unused g- Figure 3a and the mutant G oligonucleotide panel located in Figure 4f . The sequence for the scrambled G oligonucleotide used in competition experiments is 5 0 -ATT GCACAGACCTCTACTAGA-3 0 Antibodies and competition oligonucleotides were added before the labeled oligonucleotides and the EMSA reactions were allowed to equilibrate on ice for 15 min before the addition of labeled oligonucleotides.
Coimmunoprecipitation U87-MG nuclear extracts (100 mg) were added to a 1.5 ml tube and the volume was increased to 500 ml with IP buffer (10 mM Tris-HCl pH 7.4, 5 mM EDTA pH 8.0, 150 mM NaCl, 0.5% NP40). Prep1 or Pbx2 antibody (3 mg) was added to the samples and rotated at 4 1C overnight. Protein G Dynabeads (100 ml) were added to the samples the next day and rotated at 4 1C for 2 h. Beads were washed three times with ice-cold TBST for 5 min. The beads were boiled in 40 ml western sample buffer, resolved on a 10% Tris-Cl Criterion gel and subjected to western blot analysis.
In vitro transcription and translation In vitro luciferase (positive control), Prep1 and Pbx2 were produced using the TNT T7 Coupled Reticulocyte Lysate System (Promega Corporation) according to the manufacturer's instructions.
